Skip to main content

Drug Interactions between alemtuzumab and betrixaban

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

alemtuzumab betrixaban

Applies to: alemtuzumab and betrixaban

MONITOR: Coadministration of alemtuzumab with antiplatelet or anticoagulant drugs may increase the risk of bleeding. Use of alemtuzumab alone has been associated with autoimmune and hemolytic anemia, thrombocytopenia, prolonged myelosuppression, bone marrow aplasia, hemophilia, and pancytopenia. The mechanism for this interaction has not been clearly delineated, but is presumably due to additive antiplatelet/anticoagulant effects.

MANAGEMENT: Caution is recommended if alemtuzumab is used concomitantly with antiplatelet or anticoagulant drugs. Patients should be monitored for increased anticoagulant effects and bleeding complications. Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.

References (4)
  1. (2001) "Product Information. Campath (alemtuzumab)." Berlex Laboratories
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Cerner Multum, Inc. "Australian Product Information."
  4. Cerner Multum, Inc. (2015) "Canadian Product Information."

Drug and food interactions

Moderate

betrixaban food

Applies to: betrixaban

ADJUST DOSING INTERVAL: Food reduces the oral bioavailability of betrixaban. When administered with a low-fat (900 calories; 20% fat) or high-fat (900 calories; 60% fat) meal, betrixaban peak plasma concentration (Cmax) and systemic exposure (AUC) decreased relative to administration in the fasting state by an average of 70% and 61%, respectively, with the low-fat meal and 50% and 48%, respectively, with the high-fat meal. The effect of food on betrixaban pharmacokinetics could be observed for up to 6 hours after meal intake.

MANAGEMENT: The manufacturer recommends taking betrixaban at the same time each day with food.

References (1)
  1. (2017) "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer